Ex-Stanford President Tessier-Lavigne’s Drug Startup Xaira Pulls In $1 Billion

Marc Tessier-Lavigne, ex-president of Stanford University, has been appointed as the CEO of a new drug development startup, Xaira Therapeutics. Tessier-Lavigne had resigned from Stanford last year amid questions about his scientific research. Xaira Therapeutics, which launched this week, has secured $1 billion in capital commitments from major Silicon Valley firms such as Sequoia Capital and Lightspeed Venture Partners.

The startup's primary goal is to utilize artificial intelligence models to discover new drugs for treating diseases. The substantial funding and Tessier-Lavigne's leadership are expected to drive the company's innovative approach to drug discovery.

Key takeaways

Marc Tessier-Lavigne, former president of Stanford University, has been appointed as the CEO of a drug development startup, Xaira Therapeutics.
Tessier-Lavigne resigned from Stanford last year due to questions about his scientific research.
Xaira Therapeutics launched with $1 billion in capital commitments from major Silicon Valley firms such as Sequoia Capital and Lightspeed Venture Partners.
The company plans to use artificial intelligence models to discover new drugs for treating diseases.

Ex-Stanford President Tessier-Lavigne’s Drug Startup Xaira Pulls In $1 Billion

Key takeaways

Discussion (0)